These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32283966)

  • 21. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Xu Y; Ballew SH; Chang AR; Inker LA; Grams ME; Shin JI
    J Am Heart Assoc; 2024 Aug; 13(16):e034641. PubMed ID: 39119973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation.
    Binding C; Blanche P; Lip GYH; Kamper AL; Lee CJY; Staerk L; Gislason G; Torp-Pedersen C; Olesen JB; Bonde AN
    Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):210-218. PubMed ID: 38402466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
    Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
    Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Chiang CE; Liao JN; Chen TJ; Lip GYH; Chen SA
    Chest; 2020 May; 157(5):1266-1277. PubMed ID: 31809694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.
    Park S; Je NK
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):656-664. PubMed ID: 34558337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF.
    Himmelreich JCL; Virdone S; Camm J; Pieper K; Harskamp RE; Oto A; Jacobson BF; Sawhney JPS; Lim TW; Gibbs H; Goto S; Haas S; Fox KAA; Jansky P; Verheugt F; Kakkar AK;
    Open Heart; 2024 Jul; 11(2):. PubMed ID: 38955399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
    Gundlund A; Staerk L; Fosbøl EL; Gadsbøll K; Sindet-Pedersen C; Bonde AN; Gislason GH; Olesen JB
    J Intern Med; 2017 Aug; 282(2):164-174. PubMed ID: 28480507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study.
    Kwon S; Lee SR; Choi EK; Lee KY; Choi J; Ahn HJ; Oh S; Lip GYH
    Vasc Health Risk Manag; 2024; 20():231-244. PubMed ID: 38774425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.